MedTrace Logo

Olopatadine Eye Drops and Allergy Skin Testing

NCT00775658 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-07-12

Study results available
· View outcomes & findings →

Summary

Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.

Conditions

  • Allergic Rhinitis
  • Allergic Conjunctivitis

Interventions

DRUG

olopatadine

olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day

DRUG

placebo

placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00775658 on ClinicalTrials.gov